Spinout

Financing or funding
#Arthritis #Financing #Investment #Rheumatology #Spinout

Anaheim Bio launches with €40 million Series A financing

Alesta Therapeutics spin-out Anaheim Bio has launched with an oversubscribed €40 million Series A financing.  The company was formed in 2026 from programmes spun out of Alesta Therapeutics and is backed by Alesta’s former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV… Read More

#Business & Investment #News #Start-up Zone

University of Melbourne
#Financing #Radiopharmaceuticals #Spinout #Start-ups #University of Melbourne

Melbourne radiopharmaceuticals spinout launches with AUD$12 million

Australian radiopharmaceuticals spinout, Skopos Bio, has launched with an AUD$12 million (US$8.3 million) seed round, led by a global investor syndicate.  The company was founded by three clinical and translational scientists from Melbourne’s Peter MacCallum Cancer Centre (Peter Mac), who continue to treat patients and lead research:… Read More

#Business & Investment #News #Start-up Zone

Neuroscience Parkinson's disease
#Ariadne Bio #Neurodegenerative disorders #Neuroscience #Parkinson's #Spinout #Start-ups

Ariadne Bio spins out to target apathy in Parkinson’s disease

Palomar Labs (formerly Negev Labs), a venture studio that builds companies around neuropsychiatric drug development programmes with prior human validation, has announced the spinout of Ariadne Bio, its first portfolio company.   Ariadne Bio launches with lead programme AB-300, a clinical-stage-ready, non-hallucinogenic serotonin 2A receptor agonist in development… Read More

#Business & Investment #News #Start-up Zone

Chemistry
#Artificial intelligence (AI) #Deep tech #Funding #Molecular medicine #Spinout #University of Glasgow

Scottish deep-tech company secures £22 million in grants

Scottish deep-tech company Chemify has received £22 million ($29.7 million) in grants from Scottish Enterprise and the UK Government.   The funding will support a significant expansion of Chemify’s capacity to digitise molecular discovery, synthesis and scale-up through a new Chemifarm.  The grant package includes £16… Read More

#Business & Investment #News

Chemify's Chemifarm
#Automation / robotics #Cellular & Molecular biology #Chemify #New facility #Spinout #University of Glasgow

Chemputation facility redefines molecular design and discovery

Chemify has unveiled its first Chemifarm—a fully automated chemistry facility regarded as the world’s most advanced laboratory for molecular design and synthesis.  Situated in Glasgow’s Maryhill district, the site unites Chemify’s AI-driven molecular-design engine with industrial-scale robotic synthesis, compressing the journey from concept to compound and accelerating… Read More

#News

Cancer tumour
#ASCO #Immunotherapy #Oncology #Rice University #Solid tumours #Spinout #Start-ups

Sentinel BioTherapeutics launches at 2025 ASCO Annual Meeting

Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting.   This is RBL’s first company spin-out since its formation in October 2024 and positions Sentinel to begin preparations ahead of the next phase of clinical development for… Read More

#Business & Investment #News #Start-up Zone

Scientist pipetting in the lab
#Cellular assays #Drug discovery #Interview #Screening #Spinout #Turning Science into Business

Turning science into business: A step-change in adherent cell-based assays

Semarion was voted one of the SLAS2025 New Product Award winners. DDW’s Diana Spencer catches up with CEO and Co-founder Jeroen Verheyen to find out how the company has bridged the worlds of science and engineering.  DS: Congratulations on being one of the SLAS2025 New Product Award winners. Read More

#Business & Investment #Exclusive Content

#Augustine Therapeutics #Financing #Neuropathy #Spinout

Biotech raises €78 million to advance HDAC6 inhibition therapies

Augustine Therapeutics has raised €78 million to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases. The proceeds from the financing will advance Augustine’s lead candidate, AGT-100216, through a Phase II proof-of-concept clinical trial in Charcot-Marie-Tooth and support significant pipeline expansion.  Jeito Capital, a global independent… Read More

#Business & Investment #News

#Business #Drug development #Drug discovery #Spinout #Start-ups #Turning Science into Business

New DDW Highlights podcast: 10 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are… Read More

#News

#Business #Drug development #Drug discovery #Spinout #Start-ups #Turning Science into Business

This week in drug discovery (3-7 March) 

News round-up for 3-7 March by DDW Senior Digital Content Editor Diana Spencer. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are coming through and sparking new life into various areas of drug discovery. The top stories: Start-up… Read More

#News

#Artificial intelligence (AI) #Oncology #Sentinal4D #Spinout #Start-ups #The Institute of Cancer Research

Precision oncology spinout hopes to expedite drug discovery

Sentinal4D, a spinout company from The Institute of Cancer Research (ICR), London, has been announced to the public after closing its first round of funding.  The new company aims to accelerate drug discovery and development to target drugs to patients, using patented artificial intelligence-driven methods for personalised… Read More

#Business & Investment #News #Start-up Zone

Machine learning concept
#Artificial intelligence (AI) #Financing #Oncology #Orakl Oncology #Spinout #Start-ups

€11m supports launch of AI-powered drug development platform

Orakl Oncology has announced an €11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors.   The new funding will be used to accelerate the company’s growth and support the launch of two new commercial products,… Read More

#Business & Investment #News #Start-up Zone

#Artificial intelligence (AI) #Automation / robotics #Intrepid Labs #Spinout #Start-ups

Canadian start-up looking to boost drug development success rates

Dr Christine Allen, Co-Founder and CEO of Intrepid Labs tells Lu Rahman why the company’s technology has the ability to streamline the drug development process and improve the success rate of getting drugs to market. Intrepid Labs is the first spin-off from the University of Toronto’s Acceleration Consortium, which received… Read More

#Exclusive Content #Start-up Zone

#Ocular diseases #Spinout #University of Birmingham

New spinout to tackle blindness with novel gel  

A new spinout has launched from the University of Birmingham targeting treatments for the leading causes of preventable blindness.  Healome Therapeutics is developing a platform that delivers a ‘pro-healing’ microenvironment for causes of preventable blindness. The company’s platform will be targeted at ocular surface diseases, which are… Read More

#News